Superluminal is a machine learning enabled drug discovery company targeting G-protein coupled receptors (GPCRs) of relevance to diseases of the endocrine system.

Superluminal has built a multicomponent platform for structure enabled drug discovery. Based on the same principles underlying Google’s AlphaFold along with physics-based principles, Superluminal’s technology allows them to predict protein conformations and key structural interactions between a drug and its target, providing unique actionable insights for developing best in class small molecule drugs.